{{ 'Go back' | translate}}

AstraZeneca’s Imfinzi combination fails advanced lung cancer study

(Reuters) – AstraZeneca said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations. The clinical trial,